Unveiling hidden genes: New drivers of cancer

Conflict of interest

Amancio Carnero is an Associate Editor of this journal.

References

[1] Colaprico A, Olsen C, Bailey MH, et al. Interpreting pathways to discover cancer driver genes with Moonlight. Nat Commun. 2020;11:69. doi: 10.1038/s41467-019-13803-0

[2] Sinkala M. Mutational landscape of cancer-driver genes across human cancers. Sci Rep. 2023;13:12742. doi: 10.1038/s41598-023-39608-2

[3] Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010;10:59-64. doi: 10.1038/nrc2771

[4] Martínez-Jiménez F, Muiños F, Sentís I, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020; 20:555-572. doi: 10.1038/s41568-020-0290-x

[5] Nielsen F, van Overeem Hansen T, Sørensen C. Hereditary breast and ovarian cancer: New genes in confined pathways. Nat Rev Cancer. 2016; 16:599-612. doi: 10.1038/nrc.2016.72

[6] Sosinsky A, Ambrose J, Cross W, et al. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. Nat Med. 2024;30:279-289. doi: 10.1038/s41591-023-02682-0

[7] Koh G, Degasperi A, Zou X, Momen S, Nik-Zainal S. Mutational signatures: Emerging concepts, caveats and clinical applications. Nat Rev Cancer. 2021;21:619-637. doi: 10.1038/s41568-021-00377-7

[8] Saito Y, Koya J, Araki M, et al. Landscape and function of multiple mutations within individual oncogenes. Nature. 2020;582:95-99. doi: 10.1038/s41586-020-2175-2

[9] Terekhanova NV, Karpova A, Liang WW, et al. Epigenetic regulation during cancer transitions across 11 tumour types. Nature. 2023;623:432-441. doi: 10.1038/s41586-023-06682-5

[10] Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer. 2012;12:572-578. doi: 10.1038/nrc3299

[11] Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022; 22:259-279. doi: 10.1038/s41568-022-00441-w

[12] Paczkowska M, Barenboim J, Sintupisut N, et al. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020;11:735. doi: 10.1038/s41467-019-13983-9

[13] Chen Q, Liu Y, Gao Y, et al. A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. Sci Data. 2022;9:587. doi: 10.1038/s41597-022-01681-z

[14] Nagasawa S, Kuze Y, Maeda I, et al. Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. Commun Biol. 2021;4:438. doi: 10.1038/s42003-021-01959-9

[15] Grassmann F, Pawitan Y, Czene K. A systems genomics approach to uncover the molecular properties of cancer genes. Sci Rep. 2020;10:18392. doi: 10.1038/s41598-020-75400-2

[16] White R, Rose K, Zon L. Zebrafish cancer: The state of the art and the path forward. Nat Rev Cancer. 2013;13: 624-636. doi: 10.1038/nrc3589

[17] Parvez S, Brandt ZJ, Peterson RT. Large-scale F 0 CRISPR screens in vivo using MIC-Drop. Nat Protoc. 2023; 18:1841-1865. doi: 10.1038/s41596-023-00821-y

[18] Li A, Chapuy B, Varelas X, Sebastiani P, Monti S. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis. Sci Rep. 2019;9:16904. doi: 10.1038/s41598-019-52886-z

[19] López-Cortés A, Paz-y-Miño C, Guerrero S, et al. OncoOmics approaches to reveal essential genes in breast cancer: A panoramic view from pathogenesis to precision medicine. Sci Rep. 2020;10:5285. doi: 10.1038/s41598-020-62279-2